Canada’s Fusion gets FDA nod for drug tests to treat solid tumors
HQ Team April 13, 2023: Fusion Pharmaceuticals, a Canada-based radiopharmaceuticals company, announced FDA clearance for its investigational new drug applications to treat solid.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team April 13, 2023: Fusion Pharmaceuticals, a Canada-based radiopharmaceuticals company, announced FDA clearance for its investigational new drug applications to treat solid.
HQ Team April 13, 2023: Merck KGaA announced the USFDA had put a hold on the initiation of new patients to test its.
HQ Team April 7, 2023: The FDA has withdrawn Netherland-based Covis Pharma’s drug meant to cut preterm birth as it failed to prove.
HQ Team April 3, 2023: BioNTech SE and Duality Biologics (Suzhou) have signed a $1.5 billion deal to develop and commercialise two cancer.
The US FDA plans to permit the use of salt substitutes in daily food, such as bread, cheeses and ketchup, to reduce the.
The FDA cleared the emergency use of bivalent Pfizer-Biotech COVID-19 vaccine for a single dose booster in children aged six months to four.
Alembic Pharmaceuticals got the USFDA note for a generic cancer treatment drug
Moderna Inc., a biotechnology company, and Merck announced that an experimental personalised cancer vaccine, based on the messenger RNA (mRNA) technology, has received.
Merck's COVID-19 pill does not stop the risk of prevention of the virus spreading to others in a household, the company stated.
GE Healthcare has pulled out 688 medical systems that evaluate diseases, trauma, abnormalities and disorders, a move which USFDA termed a most severe.